<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0&amp;ff=20231230030956&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0&amp;ff=20231230030956&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Sat, 30 Dec 2023 08:09:59 +0000</lastbuilddate>
<pubDate>Fri, 29 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Dickkopf-1: an emerging danger signal in hypertension and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38156467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 29:ehad797. doi: 10.1093/eurheartj/ehad797. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38156467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38156467</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad797>10.1093/eurheartj/ehad797</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38156467</guid>
<pubDate>Fri, 29 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Peter P Toth</dc:creator>
<dc:date>2023-12-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dickkopf-1: an emerging danger signal in hypertension and cardiovascular disease</dc:title>
<dc:identifier>pmid:38156467</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad797</dc:identifier>
</item>
<item>
<title>Mitofusin-2 Regulates Platelet Mitochondria and Function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38156445/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS: Mfn2 preserves mitochondrial phenotypes in megakaryocytes and platelets and influences platelet life span, function, and outcomes of stroke and lung injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 29. doi: 10.1161/CIRCRESAHA.123.322914. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Single-nucleotide polymorphisms linked with the rs1474868 T allele (MFN2 [mitofusin-2] T/T) in the human mitochondrial fusion protein <i>MFN2</i> gene are associated with reduced platelet MFN2 RNA expression and platelet counts. This study investigates the impact of MFN2 on megakaryocyte and platelet biology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mice with megakaryocyte/platelet deletion of <i>Mfn2</i> (<i>Mfn2</i><sup>-/-</sup> [Mfn2 conditional knockout]) were generated using Pf4-Cre crossed with floxed <i>Mfn2</i> mice. Human megakaryocytes were generated from cord blood and platelets isolated from healthy subjects genotyped for rs1474868. Ex vivo approaches assessed mitochondrial morphology, function, and platelet activation responses. In vivo measurements included endogenous/transfused platelet life span, tail bleed time, transient middle cerebral artery occlusion, and pulmonary vascular permeability/hemorrhage following lipopolysaccharide-induced acute lung injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Mitochondria was more fragmented in megakaryocytes derived from <i>Mfn2</i><sup>-/-</sup> mice and from human cord blood with MFN2 T/T genotype compared with control megakaryocytes. Human resting platelets of MFN2 T/T genotype had reduced MFN2 protein, diminished mitochondrial membrane potential, and an increased rate of phosphatidylserine exposure during ex vivo culture. Platelet counts and platelet life span were reduced in <i>Mfn2</i><sup>-/-</sup> mice accompanied by an increased rate of phosphatidylserine exposure in resting platelets, especially aged platelets, during ex vivo culture. <i>Mfn2</i><sup>-/-</sup> also decreased platelet mitochondrial membrane potential (basal) and activated mitochondrial oxygen consumption rate, reactive oxygen species generation, calcium flux, platelet-neutrophil aggregate formation, and phosphatidylserine exposure following dual agonist activation. Ultimately, <i>Mfn2</i><sup>-/-</sup> mice showed prolonged tail bleed times, decreased ischemic stroke infarct size after cerebral ischemia-reperfusion, and exacerbated pulmonary inflammatory hemorrhage following lipopolysaccharide-induced acute lung injury. Analysis of MFN2 SNPs in the iSPAAR study (Identification of SNPs Predisposing to Altered ALI Risk) identified a significant association between MFN2 and 28-day mortality in patients with acute respiratory distress syndrome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mfn2 preserves mitochondrial phenotypes in megakaryocytes and platelets and influences platelet life span, function, and outcomes of stroke and lung injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38156445/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38156445</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322914>10.1161/CIRCRESAHA.123.322914</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38156445</guid>
<pubDate>Fri, 29 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Shancy Jacob</dc:creator>
<dc:creator>Yasuhiro Kosaka</dc:creator>
<dc:creator>Seema Bhatlekar</dc:creator>
<dc:creator>Frederik Denorme</dc:creator>
<dc:creator>Haley Benzon</dc:creator>
<dc:creator>Alexandra Moody</dc:creator>
<dc:creator>Victoria Moody</dc:creator>
<dc:creator>Emilia Tugolukova</dc:creator>
<dc:creator>Grayson Hull</dc:creator>
<dc:creator>Nina Kishimoto</dc:creator>
<dc:creator>Bhanu K Manne</dc:creator>
<dc:creator>Li Guo</dc:creator>
<dc:creator>Rhonda Souvenir</dc:creator>
<dc:creator>Brayden J Seliger</dc:creator>
<dc:creator>Alicia S Eustes</dc:creator>
<dc:creator>Kelly Hoerger</dc:creator>
<dc:creator>Neal D Tolley</dc:creator>
<dc:creator>Amir N Fatahian</dc:creator>
<dc:creator>Sihem Boudina</dc:creator>
<dc:creator>David C Christiani</dc:creator>
<dc:creator>Yongyue Wei</dc:creator>
<dc:creator>Can Ju</dc:creator>
<dc:creator>Robert A Campbell</dc:creator>
<dc:creator>Matthew T Rondina</dc:creator>
<dc:creator>E Dale Abel</dc:creator>
<dc:creator>Paul F Bray</dc:creator>
<dc:creator>Andrew S Weyrich</dc:creator>
<dc:creator>Jesse W Rowley</dc:creator>
<dc:date>2023-12-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mitofusin-2 Regulates Platelet Mitochondria and Function</dc:title>
<dc:identifier>pmid:38156445</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322914</dc:identifier>
</item>
<item>
<title>Amiodarone for atrial fibrillation: a dead man walking?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38155404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 29:ehad825. doi: 10.1093/eurheartj/ehad825. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38155404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38155404</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad825>10.1093/eurheartj/ehad825</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38155404</guid>
<pubDate>Fri, 29 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Rui Providencia</dc:creator>
<dc:creator>Kishore Kukendra-Rajah</dc:creator>
<dc:creator>Sergio Barra</dc:creator>
<dc:date>2023-12-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Amiodarone for atrial fibrillation: a dead man walking?</dc:title>
<dc:identifier>pmid:38155404</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad825</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153996/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):e167. doi: 10.1161/CIR.0000000000001207. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153996/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153996</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001207>10.1161/CIR.0000000000001207</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153996</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38153996</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001207</dc:identifier>
</item>
<item>
<title>T Cells and Macrophages Drive Pathogenesis of Immune Checkpoint Inhibitor Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153995/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):67-69. doi: 10.1161/CIRCULATIONAHA.123.067189. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153995/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153995</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067189>10.1161/CIRCULATIONAHA.123.067189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153995</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Daniela Čiháková</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>T Cells and Macrophages Drive Pathogenesis of Immune Checkpoint Inhibitor Myocarditis</dc:title>
<dc:identifier>pmid:38153995</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067189</dc:identifier>
</item>
<item>
<title>Prevalence of Abnormal Coronary Function in Patients With Angina and No Obstructive Coronary Artery Disease on Coronary Computed Tomography Angiography: Insights From the CorCTA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):24-27. doi: 10.1161/CIRCULATIONAHA.123.066571. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153994</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066571>10.1161/CIRCULATIONAHA.123.066571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153994</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prevalence of Abnormal Coronary Function in Patients With Angina and No Obstructive Coronary Artery Disease on Coronary Computed Tomography Angiography: Insights From the CorCTA Trial</dc:title>
<dc:identifier>pmid:38153994</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066571</dc:identifier>
</item>
<item>
<title>Letter by Teng et al Regarding Article, "Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):73-74. doi: 10.1161/CIRCULATIONAHA.123.066215. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153993</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066215>10.1161/CIRCULATIONAHA.123.066215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153993</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Zhenqing Teng</dc:creator>
<dc:creator>Yitong Ma</dc:creator>
<dc:creator>Xiang Ma</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Teng et al Regarding Article, "Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans"</dc:title>
<dc:identifier>pmid:38153993</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066215</dc:identifier>
</item>
<item>
<title>Navigating the Observation Zone: Do Risk Scores Help Stratify Patients With Indeterminate High-Sensitivity Cardiac Troponins?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153992/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):70-72. doi: 10.1161/CIRCULATIONAHA.123.065030. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153992/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153992</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065030>10.1161/CIRCULATIONAHA.123.065030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153992</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Nicklaus P Ashburn</dc:creator>
<dc:creator>James K McCord</dc:creator>
<dc:creator>Anna C Snavely</dc:creator>
<dc:creator>Robert H Christenson</dc:creator>
<dc:creator>Fred S Apple</dc:creator>
<dc:creator>Richard M Nowak</dc:creator>
<dc:creator>William F Peacock</dc:creator>
<dc:creator>Christopher R deFilippi</dc:creator>
<dc:creator>Simon A Mahler</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Navigating the Observation Zone: Do Risk Scores Help Stratify Patients With Indeterminate High-Sensitivity Cardiac Troponins?</dc:title>
<dc:identifier>pmid:38153992</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065030</dc:identifier>
</item>
<item>
<title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153991/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):1-3. doi: 10.1161/CIR.0000000000001208. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153991/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153991</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001208>10.1161/CIR.0000000000001208</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153991</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>&lt;em>;Circulation&lt;/em>; Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38153991</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001208</dc:identifier>
</item>
<item>
<title>Letter by Ren and Sun Regarding Article, "Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 2;149(1):75-76. doi: 10.1161/CIRCULATIONAHA.123.066809. Epub 2023 Dec 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153990</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066809>10.1161/CIRCULATIONAHA.123.066809</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153990</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jian Ren</dc:creator>
<dc:creator>Ying Sun</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Ren and Sun Regarding Article, "Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans"</dc:title>
<dc:identifier>pmid:38153990</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066809</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153186/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad837. doi: 10.1093/eurheartj/ehad837. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153186/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153186</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad837>10.1093/eurheartj/ehad837</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153186</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Lale Tokgozoglu</dc:creator>
<dc:creator>Carl Orringer</dc:creator>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias</dc:title>
<dc:identifier>pmid:38153186</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad837</dc:identifier>
</item>
<item>
<title>Leveraging global coronary flow assessments to inform revascularization benefit in chronic coronary disease: time to test total heart flow</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38153129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad812. doi: 10.1093/eurheartj/ehad812. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38153129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38153129</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad812>10.1093/eurheartj/ehad812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38153129</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leveraging global coronary flow assessments to inform revascularization benefit in chronic coronary disease: time to test total heart flow</dc:title>
<dc:identifier>pmid:38153129</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad812</dc:identifier>
</item>
<item>
<title>Metabolic Communication by SGLT2 Inhibition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSION: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065517. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell-engineered heart tissue.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152989</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065517>10.1161/CIRCULATIONAHA.123.065517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152989</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Anja M Billing</dc:creator>
<dc:creator>Young Chul Kim</dc:creator>
<dc:creator>Søren Gullaksen</dc:creator>
<dc:creator>Benedikt Schrage</dc:creator>
<dc:creator>Janice Raabe</dc:creator>
<dc:creator>Arvid Hutzfeldt</dc:creator>
<dc:creator>Fatih Demir</dc:creator>
<dc:creator>Elina Kovalenko</dc:creator>
<dc:creator>Moritz Lassé</dc:creator>
<dc:creator>Aurelien Dugourd</dc:creator>
<dc:creator>Robin Fallegger</dc:creator>
<dc:creator>Birgit Klampe</dc:creator>
<dc:creator>Johannes Jaegers</dc:creator>
<dc:creator>Qing Li</dc:creator>
<dc:creator>Olha Kravtsova</dc:creator>
<dc:creator>Maria Crespo-Masip</dc:creator>
<dc:creator>Amelia Palermo</dc:creator>
<dc:creator>Robert A Fenton</dc:creator>
<dc:creator>Elion Hoxha</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Tobias B Huber</dc:creator>
<dc:creator>Esben Laugesen</dc:creator>
<dc:creator>Tanja Zeller</dc:creator>
<dc:creator>Maria Chrysopolou</dc:creator>
<dc:creator>Julio Saez-Rodriguez</dc:creator>
<dc:creator>Christina Magnussen</dc:creator>
<dc:creator>Thomas Eschenhagen</dc:creator>
<dc:creator>Alexander Staruschenko</dc:creator>
<dc:creator>Gary Siuzdak</dc:creator>
<dc:creator>Per L Poulsen</dc:creator>
<dc:creator>Clarissa Schwab</dc:creator>
<dc:creator>Friederike Cuello</dc:creator>
<dc:creator>Volker Vallon</dc:creator>
<dc:creator>Markus M Rinschen</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Metabolic Communication by SGLT2 Inhibition</dc:title>
<dc:identifier>pmid:38152989</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065517</dc:identifier>
</item>
<item>
<title>Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152968/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.064974. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Leveraging data from 522 681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6R (IL-6 receptor) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization, we assessed its effects on 3281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3301). Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease. For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 (C-X-C motif chemokine ligand 10) were associated with risk of coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease, with up to 67% of the effects of genetically downregulated IL-6 signaling on these end points mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher <i>CXCL10</i> expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152968/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152968</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064974>10.1161/CIRCULATIONAHA.123.064974</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152968</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Savvina Prapiadou</dc:creator>
<dc:creator>Luka Živković</dc:creator>
<dc:creator>Barbara Thorand</dc:creator>
<dc:creator>Marc J George</dc:creator>
<dc:creator>Sander W van der Laan</dc:creator>
<dc:creator>Rainer Malik</dc:creator>
<dc:creator>Christian Herder</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>Thor Ueland</dc:creator>
<dc:creator>Ola Kleveland</dc:creator>
<dc:creator>Pål Aukrust</dc:creator>
<dc:creator>Lars Gullestad</dc:creator>
<dc:creator>Jürgen Bernhagen</dc:creator>
<dc:creator>Gerard Pasterkamp</dc:creator>
<dc:creator>Annette Peters</dc:creator>
<dc:creator>Aroon D Hingorani</dc:creator>
<dc:creator>Jonathan Rosand</dc:creator>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Christopher D Anderson</dc:creator>
<dc:creator>Marios K Georgakis</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis</dc:title>
<dc:identifier>pmid:38152968</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064974</dc:identifier>
</item>
<item>
<title>INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS: In summary, our findings shed light on the INO80-dependent remodeling of the chromatin landscape and transcriptional networks as a major mechanism underlying cardiac dysfunction in heart failure, and suggest INO80 as a potential preventative or interventional target.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065440. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Progressive remodeling of cardiac gene expression underlies decline in cardiac function, eventually leading to heart failure. However, the major determinants of transcriptional network switching from normal to failed hearts remain to be determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this study, we integrated human samples, genetic mouse models, and genomic approaches, including bulk RNA sequencing, single-cell RNA sequencing, chromatin immunoprecipitation followed by high-throughput sequencing, and assay for transposase-accessible chromatin with high-throughput sequencing, to identify the role of chromatin remodeling complex INO80 in heart homeostasis and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The INO80 chromatin remodeling complex was abundantly expressed in mature cardiomyocytes, and its expression further increased in mouse and human heart failure. Cardiomyocyte-specific overexpression of <i>Ino80</i>, its core catalytic subunit, induced heart failure within 4 days. Combining RNA sequencing, high-throughput sequencing, and assay for transposase-accessible chromatin with high-throughput sequencing, we revealed INO80 overexpression-dependent reshaping of the nucleosomal landscape that remodeled a core set of transcription factors, most notably the MEF2 family, whose target genes were closely associated with cardiac function. Conditional cardiomyocyte-specific deletion of <i>Ino80</i> in an established mouse model of heart failure demonstrated remarkable preservation of cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In summary, our findings shed light on the INO80-dependent remodeling of the chromatin landscape and transcriptional networks as a major mechanism underlying cardiac dysfunction in heart failure, and suggest INO80 as a potential preventative or interventional target.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065440>10.1161/CIRCULATIONAHA.123.065440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152931</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Zongna Ren</dc:creator>
<dc:creator>Wanqing Zhao</dc:creator>
<dc:creator>Dandan Li</dc:creator>
<dc:creator>Peng Yu</dc:creator>
<dc:creator>Lin Mao</dc:creator>
<dc:creator>Quanyi Zhao</dc:creator>
<dc:creator>Luyan Yao</dc:creator>
<dc:creator>Xuelin Zhang</dc:creator>
<dc:creator>Yandan Liu</dc:creator>
<dc:creator>Bingying Zhou</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure</dc:title>
<dc:identifier>pmid:38152931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065440</dc:identifier>
</item>
<item>
<title>Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 28. doi: 10.1161/CIRCRESAHA.123.322757. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are inflammatory effector cells involved in both type 2 diabetes (T2D) and atherogenesis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We investigated the relationship between circulating monocytes and cardiovascular risk progression in people with T2D, using phenotypic, transcriptomic, and metabolomic analyses. cardiovascular risk progression was estimated with coronary artery calcium score in a cohort of 672 people with T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Coronary artery calcium score was positively correlated with blood monocyte count and frequency of the classical monocyte subtype. Unsupervised k-means clustering based on monocyte subtype profiles revealed 3 main endotypes of people with T2D at varying risk of cardiovascular events. These observations were confirmed in a validation cohort of 279 T2D participants. The predictive association between monocyte count and major adverse cardiovascular events was validated through an independent prospective cohort of 757 patients with T2D. Integration of monocyte transcriptome analyses and plasma metabolomes showed a disruption of mitochondrial pathways (tricarboxylic acid cycle, oxidative phosphorylation pathway) that underlined a proatherogenic phenotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04353869.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152893</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322757>10.1161/CIRCRESAHA.123.322757</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152893</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jean-Baptiste Julla</dc:creator>
<dc:creator>Diane Girard</dc:creator>
<dc:creator>Marc Diedisheim</dc:creator>
<dc:creator>Pierre-Jean Saulnier</dc:creator>
<dc:creator>Bao Tran Vuong</dc:creator>
<dc:creator>Camille Blériot</dc:creator>
<dc:creator>Elena Carcarino</dc:creator>
<dc:creator>Joe De Keizer</dc:creator>
<dc:creator>Lucie Orliaguet</dc:creator>
<dc:creator>Ivan Nemazanyy</dc:creator>
<dc:creator>Charline Potier</dc:creator>
<dc:creator>Kennan Khider</dc:creator>
<dc:creator>Dorothy Chepngenoh Tonui</dc:creator>
<dc:creator>Tina Ejlalmanesh</dc:creator>
<dc:creator>Raphaelle Ballaire</dc:creator>
<dc:creator>Hendrick Mambu Mambueni</dc:creator>
<dc:creator>Stéphane Germain</dc:creator>
<dc:creator>Bénédicte Gaborit</dc:creator>
<dc:creator>Tiphaine Vidal-Trécan</dc:creator>
<dc:creator>Jean-Pierre Riveline</dc:creator>
<dc:creator>Henri-Jean Garchon</dc:creator>
<dc:creator>François Fenaille</dc:creator>
<dc:creator>Sophie Lemoine</dc:creator>
<dc:creator>Louis Potier</dc:creator>
<dc:creator>Florence Castelli</dc:creator>
<dc:creator>Aurélie Carlier</dc:creator>
<dc:creator>David Masson</dc:creator>
<dc:creator>Ronan Roussel</dc:creator>
<dc:creator>Claire Vandiedonck</dc:creator>
<dc:creator>Samy Hadjadj</dc:creator>
<dc:creator>Fawaz Alzaid</dc:creator>
<dc:creator>Jean-François Gautier</dc:creator>
<dc:creator>Nicolas Venteclef</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes</dc:title>
<dc:identifier>pmid:38152893</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322757</dc:identifier>
</item>
<item>
<title>Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc 1: A Nationwide Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA(2)DS(2)-VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA(2)DS(2)-VASc 2) and a higher incidence compared with CHA(2)DS(2)-VASc 0. No statistically significant difference was identified between the subgroups of CHA(2)DS(2)-VASc 1. These findings support current recommendations that patients within this intermediate risk group could be...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Oral anticoagulation is suggested in patients with atrial fibrillation and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥1 (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65-74 years, and sex score). To assess granular differences within CHA<sub>2</sub>DS<sub>2</sub>-VASc 1, the incidence of arterial thromboembolism according to CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 subgroups was examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Danish National Patient Registry and the Danish Prescription Registry linked nationally to identify patients with atrial fibrillation from 2000 to 2021 without oral anticoagulation and categorized according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score: CHA<sub>2</sub>DS<sub>2</sub>-VASc 0 (male and female subjects); CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 (hypertension, heart failure, diabetes, vascular disease, and age 65-74 years); or CHA<sub>2</sub>DS<sub>2</sub>-VASc 2 (age ≥75 years without other risk factors). Female sex was not considered a risk factor in any risk group. The outcome was arterial thromboembolism (ischemic stroke, embolism of extremity, or transient cerebral ischemia). Study groups were compared using Cox regression analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 26 701 patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc 0 score; 22 915 with CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 (1483 patients with heart failure, 9066 with hypertension, 843 with diabetes, 770 with vascular disease, and 10 753 who were 65 to 74 years of age); and 14 525 patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc 2 (≥75 years of age without other risk factors). With a median of 1 year of observation time, the cumulative incidence of arterial thromboembolism was 0.6% (n=154 [95% CI, 0.6%-0.8%]), 1.4% (n=16 [95% CI, 0.8%-2.2%]), 1.9% (n=141 [95% CI, 1.6%-2.2%]), 1.7% (n=12 [95% CI, 0.9%-2.9%]), 2.0% (n=13 [95% CI, 1.1%-3.4%]), 2.3% (n=187 [95% CI, 2.0%-2.7%]), and 4.4% (n=533 [95% CI, 4.1%-4.8%]) for CHA<sub>2</sub>DS<sub>2</sub>-VASc 0, heart failure, hypertension, diabetes, vascular disease, age 65 to 74 years (CHA<sub>2</sub>DS<sub>2</sub>-VASc 1), and age ≥75 years (CHA<sub>2</sub>DS<sub>2</sub>-VASc 2), respectively. No statistically significant difference was identified among subgroups of CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 (<i>P</i>=0.15 for difference).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with atrial fibrillation, all subgroups of CHA<sub>2</sub>DS<sub>2</sub>-VASc 1 were associated with lower incidence of arterial thromboembolism compared with age ≥75 years without other risk factors (ie, CHA<sub>2</sub>DS<sub>2</sub>-VASc 2) and a higher incidence compared with CHA<sub>2</sub>DS<sub>2</sub>-VASc 0. No statistically significant difference was identified between the subgroups of CHA<sub>2</sub>DS<sub>2</sub>-VASc 1. These findings support current recommendations that patients within this intermediate risk group could be identified with a similar risk of arterial thromboembolism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152890</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066477>10.1161/CIRCULATIONAHA.123.066477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152890</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Jonas Bjerring Olesen</dc:creator>
<dc:creator>Jeppe Kofoed Petersen</dc:creator>
<dc:creator>Lukas Schak Nielsen</dc:creator>
<dc:creator>Søren Lund Kristensen</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Emil Fosbøl</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc 1: A Nationwide Study</dc:title>
<dc:identifier>pmid:38152890</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066477</dc:identifier>
</item>
<item>
<title>Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS: These findings establish a novel DKK1-LRP5/6-GPCR pathway in inducing diabetic injuries and may resolve the long-standing conundrum as to why elevated blood DKK1 has deleterious effects. Thus, monitoring and therapeutic elimination of blood DKK1 may be a promising strategy to attenuate diabetic injuries.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad842. doi: 10.1093/eurheartj/ehad842. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Anti-hypertensive agents are one of the most frequently used drugs worldwide. However, no blood pressure-lowering strategy is superior to placebo with respect to survival in diabetic hypertensive patients. Previous findings show that Wnt co-receptors LDL receptor-related proteins 5 and 6 (LRP5/6) can directly bind to several G protein-coupled receptors (GPCRs). Because angiotensin II type 1 receptor (AT1R) is the most important GPCR in regulating hypertension, this study examines the possible mechanistic association between LRP5/6 and their binding protein Dickkopf-1 (DKK1) and activation of the AT1R and further hypothesizes that the LRP5/6-GPCR interaction may affect hypertension and potentiate cardiac impairment in the setting of diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The roles of serum DKK1 and DKK1-LRP5/6 signalling in diabetic injuries were investigated in human and diabetic mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Blood pressure up-regulation positively correlated with serum DKK1 elevations in humans. Notably, LRP5/6 physically and functionally interacted with AT1R. The loss of membrane LRP5/6 caused by injection of a recombinant DKK1 protein or conditional LRP5/6 deletions resulted in AT1R activation and hypertension, as well as β-arrestin1 activation and cardiac impairment, possibly because of multiple GPCR alterations. Importantly, unlike commonly used anti-hypertensive agents, administration of the anti-DKK1 neutralizing antibody effectively prevented diabetic cardiac impairment in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings establish a novel DKK1-LRP5/6-GPCR pathway in inducing diabetic injuries and may resolve the long-standing conundrum as to why elevated blood DKK1 has deleterious effects. Thus, monitoring and therapeutic elimination of blood DKK1 may be a promising strategy to attenuate diabetic injuries.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152853</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad842>10.1093/eurheartj/ehad842</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152853</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>En Ma</dc:creator>
<dc:creator>Da Wo</dc:creator>
<dc:creator>Jinxiao Chen</dc:creator>
<dc:creator>Hongwei Yan</dc:creator>
<dc:creator>Xiaohui Zhou</dc:creator>
<dc:creator>Jia He</dc:creator>
<dc:creator>Celiang Wu</dc:creator>
<dc:creator>Qing Wang</dc:creator>
<dc:creator>Changjing Zuo</dc:creator>
<dc:creator>Xiao Li</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Qingshu Meng</dc:creator>
<dc:creator>Liang Zheng</dc:creator>
<dc:creator>Luying Peng</dc:creator>
<dc:creator>Lidian Chen</dc:creator>
<dc:creator>Jun Peng</dc:creator>
<dc:creator>Dan-Ni Ren</dc:creator>
<dc:creator>Weidong Zhu</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice</dc:title>
<dc:identifier>pmid:38152853</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad842</dc:identifier>
</item>
<item>
<title>Fibrosing mediastinitis manifesting as refractory pleural effusion and severe pulmonary hypertension successfully treated by percutaneous pulmonary vein stenting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152845/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad862. doi: 10.1093/eurheartj/ehad862. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152845/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152845</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad862>10.1093/eurheartj/ehad862</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152845</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Ziling He</dc:creator>
<dc:creator>Danping Zhang</dc:creator>
<dc:creator>Xuefeng Wang</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fibrosing mediastinitis manifesting as refractory pleural effusion and severe pulmonary hypertension successfully treated by percutaneous pulmonary vein stenting</dc:title>
<dc:identifier>pmid:38152845</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad862</dc:identifier>
</item>
<item>
<title>Gastropericardial fistula complicated by severe multi-vessel coronary spasm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38152844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 28:ehad860. doi: 10.1093/eurheartj/ehad860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38152844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38152844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad860>10.1093/eurheartj/ehad860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38152844</guid>
<pubDate>Thu, 28 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Qianfeng Xiao</dc:creator>
<dc:creator>Ying Xu</dc:creator>
<dc:creator>Si Wang</dc:creator>
<dc:date>2023-12-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gastropericardial fistula complicated by severe multi-vessel coronary spasm</dc:title>
<dc:identifier>pmid:38152844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad860</dc:identifier>
</item>
<item>
<title>Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38150260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231230030956&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the STRONG-HF randomized clinical trial show that, among patients randomly assigned to high-intensity care, achieving higher doses of HF GDMT 2 weeks after discharge was feasible and safe in most patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 27:e234553. doi: 10.1001/jamacardio.2023.4553. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro-Brain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) trial strived for rapid uptitration aiming to reach 100% optimal doses of guideline-directed medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the association between degree of GDMT doses achieved in high-intensity care and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the STRONG-HF randomized clinical trial, conducted from May 2018 to September 2022. Included in the study were patients with AHF who were not treated with optimal doses of GDMT before and after discharge from an AHF admission. Data were analyzed from January to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: The mean percentage of the doses of 3 classes of HF medications (renin-angiotensin system inhibitors, β-blockers, and mineralocorticoid receptor antagonists) relative to their optimal doses was computed. Patients were classified into 3 dose categories: low (&lt;50%), medium (≥50% to &lt;90%), and high (≥90%). Dose and dose group were included as a time-dependent covariate in Cox regression models, which were used to test whether outcomes differed by dose.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME MEASURES: Post hoc secondary analyses of postdischarge 180-day HF readmission or death and 90-day change in quality of life.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 515 patients (mean [SD] age, 62.7 [13.4] years; 311 male [60.4%]) assigned high-intensity care were included in this analysis. At 2 weeks, 39 patients (7.6%) achieved low doses, 254 patients (49.3%) achieved medium doses, and 222 patients (43.1%) achieved high doses. Patients with lower blood pressure and more congestion were less likely to be uptitrated to optimal GDMT doses at week 2. As a continuous time-dependent covariate, an increase of 10% in the average percentage optimal dose was associated with a reduction in 180-day HF readmission or all-cause death (primary end point: adjusted hazard ratio [aHR], 0.89; 95% CI, 0.81-0.98; P = .01) and a decrease in 180-day all-cause mortality (aHR, 0.84; 95% CI, 0.73-0.95; P = .007). Quality of life at 90 days, measured by the EQ-5D visual analog scale, improved more in patients treated with higher doses of GDMT (mean difference, 0.10; 95% CI, -4.88 to 5.07 and 3.13; 95% CI, -1.98 to 8.24 points in the medium- and high-dose groups relative to the low-dose group, respectively; P = .07). Adverse events to day 90 occurred less frequently in participants with HIC who were prescribed higher GDMT doses at week 2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this post hoc analysis of the STRONG-HF randomized clinical trial show that, among patients randomly assigned to high-intensity care, achieving higher doses of HF GDMT 2 weeks after discharge was feasible and safe in most patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03412201.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38150260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">38150260</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10753435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231230030956&v=2.18.0">PMC10753435</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4553>10.1001/jamacardio.2023.4553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38150260</guid>
<pubDate>Wed, 27 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gad Cotter</dc:creator>
<dc:creator>Benjamin Deniau</dc:creator>
<dc:creator>Beth Davison</dc:creator>
<dc:creator>Christopher Edwards</dc:creator>
<dc:creator>Marianna Adamo</dc:creator>
<dc:creator>Mattia Arrigo</dc:creator>
<dc:creator>Marianela Barros</dc:creator>
<dc:creator>Jan Biegus</dc:creator>
<dc:creator>Jelena Celutkiene</dc:creator>
<dc:creator>Kamile Cerlinskaite-Bajore</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:creator>Alain Cohen-Solal</dc:creator>
<dc:creator>Albertino Damasceno</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Etienne Gayat</dc:creator>
<dc:creator>Antoine Kimmoun</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Maria Novosadova</dc:creator>
<dc:creator>Peter S Pang</dc:creator>
<dc:creator>Matteo Pagnesi</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Hadiza Saidu</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Koji Takagi</dc:creator>
<dc:creator>Jozine M Ter Maaten</dc:creator>
<dc:creator>Daniela Tomasoni</dc:creator>
<dc:creator>Adriaan Voors</dc:creator>
<dc:creator>Alexandre Mebazaa</dc:creator>
<dc:date>2023-12-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38150260</dc:identifier>
<dc:identifier>pmc:PMC10753435</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4553</dc:identifier>
</item>





























</channel>
</rss>